Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP2802 CAR-T cell therapy with MA-20 in CD20-positive B-cell lymphomas
NCT06248086Phase 1Terminated
- Sponsor
- Astellas Pharma
- Start
- Sep 2024
- Primary completion
- Dec 2024
- Modality
- CAR-T Cells, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ASP2802 in B cell lymphoma (3 arms), sponsored by Astellas Pharma. Primary endpoints: Dose Limiting Toxicities at 10 months, Adverse Events at 26 months and 5 more. Started Sep 2024; status: terminated.
02
Drugs
ASP2802
03
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT06248086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06248086.